Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scilex Holding CoFRA:D8B0 -9.86%39 Piotroski F-Score is 2 as of Jul. 22, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates FRA:D8B0 with a GF Score™ of 39/100 and a GF Value™ of €4.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 979 Drug Manufacturers companies, Scilex Holding Co ranks worse than 91.42% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Scilex Holding Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Scilex Holding Co's Piotroski F-Score or its related term are showing as below:
FRA:D8B0'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 6
Current: 2
During the past 7 years, the highest Piotroski F-Score of Scilex Holding Co was 6. The lowest was 2. And the median was 3.
Scilex Holding Co (FRA:D8B0) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Scilex Holding Co Piotroski F-Score Related Terms
Scilex Holding Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:D8B0 vs MIRA, NSRX, MDCX: Piotroski F-Score Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Scilex Holding Co's current Net Income (TTM) was -321.55.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Scilex Holding Co's return on assets of this year was -4.40161253. Scilex Holding Co's return on assets of last year was -0.82392395.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Scilex Holding Co's gearing of this year was 0.05797195. Scilex Holding Co's gearing of last year was 0.01415643.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Scilex Holding Co's current ratio of this year was 0.08364688. Scilex Holding Co's current ratio of last year was 0.10409585.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Scilex Holding Co's number of shares in issue this year was 6.891. Scilex Holding Co's number of shares in issue last year was 11.565.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Scilex Holding Co's gross margin of this year was 0.59646291. Scilex Holding Co's gross margin of last year was 0.71884692.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Scilex Holding Co's asset turnover of this year was 0.3986147. Scilex Holding Co's asset turnover of last year was 0.56079866.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
1
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Scilex Holding Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Scilex Holding Co (FRA:D8B0) has a Piotroski F-Score of 2 as of Jul. 22, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Scilex Holding Co and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Scilex Holding Co's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Scilex Holding Co ranks #895 out of 979 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is Scilex Holding Co's Piotroski F-Score too high?
Scilex Holding Co's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Scilex Holding Co's value of 2 is 60% below this industry median. Based on the distribution chart, Scilex Holding Co ranks #895 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Scilex Holding Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Piotroski F-Score compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #895 out of 979 companies for Piotroski F-Score. This places Scilex Holding Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Scilex Holding Co's value of 2 is 60% below this benchmark. Historically, Scilex Holding Co's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Scilex Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scilex Holding Co's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (FRA:D8B0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.77, compared to a current price of €6.40 — trading 34.2% above its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 60% below the Drug Manufacturers industry median of 5.00. Scilex Holding Co's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Scilex Holding Co (FRA:D8B0), the current Piotroski F-Score is 2 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of €6.40 is trading 34.2% above its estimated GF Value™ of €4.77.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for FRA:D8B0:
Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
GF Value™: €4.77 vs. price of €6.40 (34.2% above fair value)
Industry Position: 60% below the Drug Manufacturers median (#895 of 979)
No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score
Get the complete analysis for FRA:D8B0
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D8B0 has been successfully added to your 
